NCT04753216
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +23 more
- Locations
-
- Northwestern University Chicago, Illinois, United States
Clinical trial condition
Platinum-Resistant Ovarian Carcinoma
Explore clinical trials studying Platinum-Resistant Ovarian Carcinoma. Study availability and eligibility vary by location and protocol.
20 public trials
4 recruiting studies
Platinum-Resistant Ovarian Carcinoma trial results
Active, Not Recruiting
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
NCT02298959
- Conditions
- Adenocarcinoma, Adnexal Diseases, Carcinoma, +60 more
- Locations
-
- Moffitt Cancer Center-International Plaza Tampa, Florida, United States
- Moffitt Cancer Center - McKinley Campus Tampa, Florida, United States
- Moffitt Cancer Center Tampa, Florida, United States
- National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
Active, Not Recruiting
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
NCT05465941
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +20 more
- Locations
-
- Mayo Clinic Rochester, Minnesota, United States
Active, Not Recruiting
Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors
NCT04616534
- Conditions
- Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +40 more
- Locations
-
- National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States
- National Institutes of Health Clinical Center Bethesda, Maryland, United States
- Dana-Farber Cancer Institute Boston, Massachusetts, United States
Active, Not Recruiting
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
NCT02650986
- Conditions
- Adnexal Diseases, Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, +78 more
- Locations
-
- Roswell Park Cancer Institute Buffalo, New York, United States
Active, Not Recruiting
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03587311
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, +5 more
- Locations
-
- UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
- UCHealth University of Colorado Hospital Aurora, Colorado, United States
- UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States
Active, Not Recruiting
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
NCT03449108
- Conditions
- Adnexal Diseases, Bone Diseases, Bone Neoplasms, +49 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
NCT01970722
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +43 more
- Locations
-
- City of Hope Corona Corona, California, United States
- City of Hope Medical Center Duarte, California, United States
- City of Hope Upland Upland, California, United States
- Parkview Hospital Randallia Fort Wayne, Indiana, United States
Active, Not Recruiting
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04781088
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +24 more
- Locations
-
- Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
- Allegheny Health Network Pittsburgh, Pennsylvania, United States
Active, Not Recruiting
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT03907527
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +48 more
- Locations
-
- National Institutes of Health (NIH) Bethesda, Maryland, United States
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States